Guangyao Lin1, Bei Dong1, Yuzhou Li1, Wenqi Huang1. 1. Medical Imaging Center, The First People's Hospital of Shangqiu City No. 292, Kai Xuan Nan Road, Shangqiu 476100, Henan, China.
Abstract
OBJECTIVE: To determine the diagnostic value of cardiac magnetic resonance imaging (CMRI) for myocardial fibrosis (MF) in patients with heart failure (HF) and its predictive value for prognosis. METHODS: A total of 180 patients with heart failure who were hospitalized in the Cardiology Department of The First People's Hospital of Shangqiu City from September 2019 to May 2021 were selected and assigned to Group B (n=80) given levosimendan and Group A (n=100) given levosimendan combined with ivabradine hydrochloride. The cardiac function indicators (left ventricular end-systolic volume (LVESV), left ventricular ejection fraction (LVEF), and left ventricular end-systolic diameter (LVESD) were measured by nuclear magnetic resonance (MRI). Myocardial fibrosis (MF)-related indicators (pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen (ICTP), N-terminal propeptide of procollagen type III (PIIINP), connective tissue growth factor (CTGF), and hyaluronic acid (HA), inflammatory factors (Hs-CRP and IL-8) were measured using ELISA. Quality of life (QoL) and physical recovery (6-min walking test (6MWT), Fugl-Meyer Assessment (FMA), and Barthel index) of the two groups were compared. The late gadolinium enhancement (LGE) was used to analyze the occurrence of MF in patients. The patients were further divided into the LGE (+) group (cases) and LGE (-) group (cases). The changes of cardiac function indicators before treatment were analyzed, and their predictive value was analyzed. RESULTS: Compared with Group B, Group A showed a lower incidence of complications, and presented a higher LVEF level and lower levels of LVESV, LVESD, ICTP, PIIINP, CTGF, HA, LN, and inflammatory factors. The area under the curves of LVESV, LVESD, and LVEF in predicting MF were all >0.7. CONCLUSION: Levosimendan combined with ivabradine hydrochloride can effectively alleviate MF in patients with MF, and CMRI has a good predictive value for MF in such patients, which is worthy of clinical promotion. AJTR
OBJECTIVE: To determine the diagnostic value of cardiac magnetic resonance imaging (CMRI) for myocardial fibrosis (MF) in patients with heart failure (HF) and its predictive value for prognosis. METHODS: A total of 180 patients with heart failure who were hospitalized in the Cardiology Department of The First People's Hospital of Shangqiu City from September 2019 to May 2021 were selected and assigned to Group B (n=80) given levosimendan and Group A (n=100) given levosimendan combined with ivabradine hydrochloride. The cardiac function indicators (left ventricular end-systolic volume (LVESV), left ventricular ejection fraction (LVEF), and left ventricular end-systolic diameter (LVESD) were measured by nuclear magnetic resonance (MRI). Myocardial fibrosis (MF)-related indicators (pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen (ICTP), N-terminal propeptide of procollagen type III (PIIINP), connective tissue growth factor (CTGF), and hyaluronic acid (HA), inflammatory factors (Hs-CRP and IL-8) were measured using ELISA. Quality of life (QoL) and physical recovery (6-min walking test (6MWT), Fugl-Meyer Assessment (FMA), and Barthel index) of the two groups were compared. The late gadolinium enhancement (LGE) was used to analyze the occurrence of MF in patients. The patients were further divided into the LGE (+) group (cases) and LGE (-) group (cases). The changes of cardiac function indicators before treatment were analyzed, and their predictive value was analyzed. RESULTS: Compared with Group B, Group A showed a lower incidence of complications, and presented a higher LVEF level and lower levels of LVESV, LVESD, ICTP, PIIINP, CTGF, HA, LN, and inflammatory factors. The area under the curves of LVESV, LVESD, and LVEF in predicting MF were all >0.7. CONCLUSION: Levosimendan combined with ivabradine hydrochloride can effectively alleviate MF in patients with MF, and CMRI has a good predictive value for MF in such patients, which is worthy of clinical promotion. AJTR
Authors: Frank Edelmann; Christoph Knosalla; Klaus Mörike; Christiane Muth; Peggy Prien; Stefan Störk Journal: Dtsch Arztebl Int Date: 2018-02-23 Impact factor: 5.594
Authors: Vasileios Askoxylakis; Christian Thieke; Sven T Pleger; Patrick Most; Judith Tanner; Katja Lindel; Hugo A Katus; Jürgen Debus; Marc Bischof Journal: BMC Cancer Date: 2010-03-22 Impact factor: 4.430
Authors: Leda Tomiko Yamada da Silveira; Janete Maria da Silva; Júlia Maria Pavan Soler; Carolina Yea Ling Sun; Clarice Tanaka; Carolina Fu Journal: Int J Qual Health Care Date: 2018-05-01 Impact factor: 2.038
Authors: Ahmad Shoaib; Harriette G C Van Spall; Jianhua Wu; John G F Cleland; Theresa A McDonagh; Muhammad Rashid; Mohamed O Mohamed; Fozia Z Ahmed; John Deanfield; Mark de Belder; Chris P Gale; Mamas A Mamas Journal: Eur Heart J Qual Care Clin Outcomes Date: 2021-05-27
Authors: Bruce A Warden; Johannes Steiner; Albert Camacho; Khoa Nguyen; Jonathan Q Purnell; P Barton Duell; Courtney Craigan; Diane Osborn; Sergio Fazio Journal: Am J Prev Cardiol Date: 2021-04-15